BR112013033544A2 - dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos - Google Patents
dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicosInfo
- Publication number
- BR112013033544A2 BR112013033544A2 BR112013033544A BR112013033544A BR112013033544A2 BR 112013033544 A2 BR112013033544 A2 BR 112013033544A2 BR 112013033544 A BR112013033544 A BR 112013033544A BR 112013033544 A BR112013033544 A BR 112013033544A BR 112013033544 A2 BR112013033544 A2 BR 112013033544A2
- Authority
- BR
- Brazil
- Prior art keywords
- paclitaxel
- treatment
- dosage
- administration
- gynecological cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229930012538 Paclitaxel Natural products 0.000 title abstract 4
- 229960001592 paclitaxel Drugs 0.000 title abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
abstract provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-erbb3 antibodies combined with paclitaxel. tradução do resumo resumo patente de invenção: "dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos". são providos métodos e composições para tratamento clínico de cânceres ginecológicos avançados utilizando anticorpos anti-erbb3 combinados com paclitaxel.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503342P | 2011-06-30 | 2011-06-30 | |
| US201161529630P | 2011-08-31 | 2011-08-31 | |
| FR1250860 | 2012-01-30 | ||
| US201261596102P | 2012-02-07 | 2012-02-07 | |
| PCT/US2012/042164 WO2013003037A2 (en) | 2011-06-30 | 2012-06-13 | Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013033544A2 true BR112013033544A2 (pt) | 2017-12-19 |
Family
ID=47424747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013033544A BR112013033544A2 (pt) | 2011-06-30 | 2012-06-13 | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140248280A1 (pt) |
| EP (1) | EP2726100A4 (pt) |
| JP (1) | JP2014527035A (pt) |
| KR (1) | KR20140063578A (pt) |
| CN (1) | CN103945866A (pt) |
| AU (1) | AU2012275850A1 (pt) |
| BR (1) | BR112013033544A2 (pt) |
| CA (1) | CA2839869A1 (pt) |
| CO (1) | CO6862110A2 (pt) |
| EA (1) | EA201490180A1 (pt) |
| MA (1) | MA35281B1 (pt) |
| MX (1) | MX2013015333A (pt) |
| PH (1) | PH12013502663A1 (pt) |
| TW (1) | TW201317002A (pt) |
| UY (1) | UY34178A (pt) |
| WO (1) | WO2013003037A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
| CN104755499B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| JP6755235B2 (ja) * | 2014-07-16 | 2020-09-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 低悪性度漿液性癌におけるｈｅｒ３阻害 |
| CA2983008A1 (en) | 2015-04-17 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| SG11201806251WA (en) | 2016-03-15 | 2018-08-30 | Merrimack Pharmaceuticals Inc | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073629A2 (en) * | 2006-11-03 | 2008-06-19 | Board Of Regents, The University Of Texas System | Bifunctional predictors of cancer treatment sensitivity and resistance |
| BRPI0808055A2 (pt) * | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| PL2544680T3 (pl) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
-
2012
- 2012-06-13 EP EP12803745.4A patent/EP2726100A4/en not_active Withdrawn
- 2012-06-13 US US14/130,058 patent/US20140248280A1/en not_active Abandoned
- 2012-06-13 CN CN201280041592.0A patent/CN103945866A/zh active Pending
- 2012-06-13 BR BR112013033544A patent/BR112013033544A2/pt not_active IP Right Cessation
- 2012-06-13 CA CA2839869A patent/CA2839869A1/en not_active Abandoned
- 2012-06-13 JP JP2014518607A patent/JP2014527035A/ja active Pending
- 2012-06-13 PH PH1/2013/502663A patent/PH12013502663A1/en unknown
- 2012-06-13 KR KR1020147002211A patent/KR20140063578A/ko not_active Withdrawn
- 2012-06-13 EA EA201490180A patent/EA201490180A1/ru unknown
- 2012-06-13 AU AU2012275850A patent/AU2012275850A1/en not_active Abandoned
- 2012-06-13 WO PCT/US2012/042164 patent/WO2013003037A2/en active Application Filing
- 2012-06-13 MX MX2013015333A patent/MX2013015333A/es unknown
- 2012-06-29 UY UY0001034178A patent/UY34178A/es not_active Application Discontinuation
- 2012-06-29 TW TW101123370A patent/TW201317002A/zh unknown
-
2014
- 2014-01-22 MA MA36703A patent/MA35281B1/fr unknown
- 2014-01-29 CO CO14018361A patent/CO6862110A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2839869A1 (en) | 2013-01-03 |
| PH12013502663A1 (en) | 2018-03-21 |
| TW201317002A (zh) | 2013-05-01 |
| JP2014527035A (ja) | 2014-10-09 |
| KR20140063578A (ko) | 2014-05-27 |
| WO2013003037A3 (en) | 2014-05-01 |
| WO2013003037A2 (en) | 2013-01-03 |
| EA201490180A1 (ru) | 2014-08-29 |
| EP2726100A4 (en) | 2015-04-29 |
| UY34178A (es) | 2013-01-31 |
| MX2013015333A (es) | 2014-07-09 |
| EP2726100A2 (en) | 2014-05-07 |
| US20140248280A1 (en) | 2014-09-04 |
| CO6862110A2 (es) | 2014-02-10 |
| CN103945866A (zh) | 2014-07-23 |
| AU2012275850A1 (en) | 2013-03-21 |
| MA35281B1 (fr) | 2014-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019008I1 (el) | Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| HUE049886T2 (hu) | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra | |
| CL2014002726A1 (es) | Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14). | |
| CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
| MX2013011922A (es) | Compuestos de benceno substituido. | |
| MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
| BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
| MY162146A (en) | Pharmaceutical composition | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| IN2014DN09228A (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE FR 1250860, REIVINDICADA NO PCT/US2012/042164, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE UM DOS DEPOSITANTES CONSTANTES DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("MERRIMACK PHARMACEUTICALS, INC") SER DIVERGENTE DE UM DOS TITULARES DA PRIORIDADE REIVINDICADA ("MERRIMACK PHARMACEUTICALS") E, MESMO APOS A ELABORACAO DE EXIGENCIA PARA TAL, NAO FOI SANADA A DIVERGENCIA APONTADA. DESSA FORMA, RESTA NECESSARIA A APRESENTACAO DO DOCUMENTO COMPROBATORIO DE CESSAO DA CITADA PRIORIDADE ACOMPANHADO DE SUA RESPECTIVA TRADUCAO, O QUE NAO OCORR |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |